Hansa Biopharma — April 2024
-
Hansa Biopharma: Secures growth capital supported by two solid quarters
-
Hansa Biopharma interim report January-March 2024
• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease
• Cash runway extended into 2026
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Office -
Hansa Biopharma will host a telephone conference today Thursday, April 18, 2024, 14:00 CET / 8:00am EST.
The webcast will be available on https://hansabiopharma.eventcdn.net/events/interim-report-january-march-2024
-
Analyst Consensus (Updated 12-04-2024) Buy: 8, Hold: 1, Sell: 0.
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
-
Hansa Biopharma Q1: Improved outlook
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind